{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:02:11Z","timestamp":1769018531177,"version":"3.49.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40291-019-00398-x","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T08:03:37Z","timestamp":1554710617000},"page":"429-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis"],"prefix":"10.1007","volume":"23","author":[{"given":"Kevin","family":"Zarca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Durand-Zaleski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Anne","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Chatellier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Pallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"398_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2036.2011.04905.x","volume":"35","author":"L Chouchana","year":"2012","unstructured":"Chouchana L, Narjoz C, Beaune P, Loriot M-A, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:15\u201336.","journal-title":"Aliment Pharmacol Ther"},{"key":"398_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0162-3109(00)00186-7","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC. Immunosuppressive drugs: the first 50\u00a0years and a glance forward. Immunopharmacology. 2000;47:63\u201383.","journal-title":"Immunopharmacology."},{"key":"398_CR3","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1056\/NEJMra033540","volume":"351","author":"PF Halloran","year":"2004","unstructured":"Halloran PF. Immunosuppressive drugs for kidney transplantation. NEJM. 2004;351:2715\u201329.","journal-title":"NEJM."},{"key":"398_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.tiv.2007.12.004","volume":"22","author":"E Petit","year":"2007","unstructured":"Petit E, Langouet S, Akhdar H, Nicolas-Nicolaz C, Guillouzo A, Morel F. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol In Vitro. 2007;22:632\u201342.","journal-title":"Toxicol In Vitro"},{"key":"398_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc2292","volume":"8","author":"P Karran","year":"2008","unstructured":"Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 2008;8:24\u201336.","journal-title":"Nat Rev Cancer"},{"key":"398_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","volume":"56","author":"AL Taylor","year":"2005","unstructured":"Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56:23\u201346.","journal-title":"Crit Rev Oncol Hematol"},{"key":"398_CR7","first-page":"277","volume":"1180","author":"EH Stet","year":"1993","unstructured":"Stet EH, Abreu RAD, Janssen YP, B\u00f6kkerink JP, Trijbels FJ. A biochemical basis for synergism of 6-mercaptopurine and mycophenolic acid in Molt F4, a human malignant T-lymphoblastic cell line. Biochem Biophys Acta. 1993;1180:277\u201382.","journal-title":"Biochem Biophys Acta"},{"issue":"78","key":"398_CR8","first-page":"1","volume":"13","author":"H-Y Huang","year":"2016","unstructured":"Huang H-Y, Chang H-F, Tsai M-J, Chen J-S, Wang M-J. 6-mercaptopurine attenuates tumor necrosis factor-\u03b1 production in microglia through Nur77-mediated transrepression and PI3K\/Akt\/mTOR signaling-mediated translational regulation. J Neuroinflamm. 2016;13(78):1\u201320.","journal-title":"J Neuroinflamm"},{"key":"398_CR9","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.transproceed.2016.01.084","volume":"48","author":"D Zochowska","year":"2016","unstructured":"Zochowska D, Zegarska J, Hryniewiecka E, Samborowska E, Jazwiec R, Tszyrsznic W, et al. Determination of concentrations of azathioprine metabolites 6-thioguanine and 6-methylmercaptopurine in whole blood with the use of liquid chromatography combined with mass spectrometry. Transplant Proc. 2016;48:1836\u20139.","journal-title":"Transplant Proc."},{"key":"398_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ng.3508","volume":"48","author":"T Moriyama","year":"2016","unstructured":"Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann F-A, Zhao X, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48:367\u201373.","journal-title":"Nat Genet"},{"issue":"10","key":"398_CR11","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1046\/j.1365-2036.2002.01353.x","volume":"16","author":"A Ansari","year":"2002","unstructured":"Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16(10):1743\u201350.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"398_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1124\/pr.58.3.6","volume":"58","author":"SJ Gardiner","year":"2006","unstructured":"Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58(3):521\u201390.","journal-title":"Pharmacol Rev"},{"issue":"4","key":"398_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2125.2005.02474.x","volume":"62","author":"SJ Gardiner","year":"2006","unstructured":"Gardiner SJ, Gearry RB, Barclay ML, Begg EJ. Two cases of thiopurine methyltransferase (TPMT) deficiency\u2014a lucky save and a near miss with azathioprine. Br J Clin Pharmacol. 2006;62(4):473\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"398_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2165\/00019053-200624080-00004","volume":"24","author":"VL Priest","year":"2006","unstructured":"Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Gearry RB, Barclay ML, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics. 2006;24(8):767\u201381.","journal-title":"Pharmacoeconomics."},{"issue":"7","key":"398_CR15","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1111\/j.1572-0241.2008.01848.x","volume":"103","author":"JP Gisbert","year":"2008","unstructured":"Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008;103(7):1783\u2013800.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"398_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000028394","volume":"61","author":"EY Krynetski","year":"2000","unstructured":"Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology. 2000;61(3):136\u201346.","journal-title":"Pharmacology"},{"issue":"4","key":"398_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/sj.leu.2401723","volume":"14","author":"HL McLeod","year":"2000","unstructured":"McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 2000;14(4):567\u201372.","journal-title":"Leukemia"},{"issue":"8","key":"398_CR18","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/gut.34.8.1081","volume":"34","author":"WR Connell","year":"1993","unstructured":"Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27\u00a0years of experience. Gut. 1993;34(8):1081\u20135.","journal-title":"Gut"},{"issue":"5","key":"398_CR19","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/00007691-199710000-00003","volume":"19","author":"S Bergan","year":"1997","unstructured":"Bergan S, Bentdal O, Sodal G, Brun A, Rugstad HE, Stokke O. Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts. Ther Drug Monit. 1997;19(5):502\u20139.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"398_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/00008571-200208000-00003","volume":"12","author":"M Schwab","year":"2002","unstructured":"Schwab M, Schaffeler E, Marx C, Fischer C, Lang T, Behrens C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002;12(6):429\u201336.","journal-title":"Pharmacogenetics."},{"issue":"6","key":"398_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1136\/ard.47.6.503","volume":"47","author":"ME Jeurissen","year":"1988","unstructured":"Jeurissen ME, Boerbooms AM, van de Putte LB. Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis. 1988;47(6):503\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"398_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cgh.2005.10.019","volume":"4","author":"Z Zelinkova","year":"2006","unstructured":"Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen AH, Curvers WL, et al. Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006;4(1):44\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"398_CR23","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1158\/0008-5472.CAN-06-3508","volume":"67","author":"C Hartford","year":"2007","unstructured":"Hartford C, Vasquez E, Schwab M, Edick MJ, Rehg JE, Grosveld G, et al. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res. 2007;67(10):4965\u201372.","journal-title":"Cancer Res"},{"issue":"13","key":"398_CR24","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.clinbiochem.2011.06.079","volume":"44","author":"O Dewit","year":"2011","unstructured":"Dewit O, Moreels T, Baert F, Peeters H, Reenaers C, de Vos M, et al. Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clin Biochem. 2011;44(13):1062\u20136.","journal-title":"Clin Biochem"},{"issue":"6","key":"398_CR25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0016-5085(00)70354-4","volume":"118","author":"JF Colombel","year":"2000","unstructured":"Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn\u2019s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118(6):1025\u201330.","journal-title":"Gastroenterology"},{"issue":"6","key":"398_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2217\/pgs.14.32","volume":"15","author":"L Chouchana","year":"2014","unstructured":"Chouchana L, Narjoz C, Roche D, Golmard JL, Pineau B, Chatellier G, et al. Interindividual variability in TPMT enzyme activity: 10\u00a0years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring. Pharmacogenomics. 2014;15(6):745\u201357.","journal-title":"Pharmacogenomics."},{"issue":"4","key":"398_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/00008571-199208000-00002","volume":"2","author":"CL Szumlanski","year":"1992","unstructured":"Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics. 1992;2(4):148\u201359.","journal-title":"Pharmacogenetics."},{"issue":"2","key":"398_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00228-004-0732-5","volume":"60","author":"C Ganiere-Monteil","year":"2004","unstructured":"Ganiere-Monteil C, Medard Y, Lejus C, Bruneau B, Pineau A, Fenneteau O, et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol. 2004;60(2):89\u201396.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"398_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/00007691-200412000-00014","volume":"26","author":"U Hindorf","year":"2004","unstructured":"Hindorf U, Peterson C, Almer S. Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population. Ther Drug Monit. 2004;26(6):673\u20138.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"398_CR30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/0272989X18754513","volume":"38","author":"EM Krijkamp","year":"2018","unstructured":"Krijkamp EM, Alarid-Escudero F, Enns EA, Jalal HJ, Hunink MGM, Pechlivanoglou P. Microsimulation modeling for health decision sciences using R: a tutorial. Med Decis Mak. 2018;38(3):400\u201322.","journal-title":"Med Decis Mak"},{"issue":"11","key":"398_CR31","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.2217\/pgs.09.103","volume":"10","author":"L Serpe","year":"2009","unstructured":"Serpe L, Calvo PL, Muntoni E, D\u2019Antico S, Giaccone M, Avagnina A, et al. Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity. Pharmacogenomics. 2009;10(11):1753\u201365.","journal-title":"Pharmacogenomics."},{"issue":"1","key":"398_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/bcp.12066","volume":"76","author":"L Lennard","year":"2013","unstructured":"Lennard L, Cartwright CS, Wade R, Richards SM, Vora A. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol. 2013;76(1):125\u201336.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"398_CR33","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.bcp.2009.03.006","volume":"77","author":"M Milek","year":"2009","unstructured":"Milek M, Karas Kuzelicki N, Smid A, Mlinaric-Rascan I. S-adenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts. Biochem Pharmacol. 2009;77(12):1845\u201353.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"398_CR34","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/00007890-199510150-00003","volume":"60","author":"J Mircheva","year":"1995","unstructured":"Mircheva J, Legendre C, Soria-Royer C, Thervet E, Beaune P, Kreis H. Monitoring of azathioprine-induced immunosuppression with thiopurine methyltransferase activity in kidney transplant recipients. Transplantation. 1995;60(7):639\u201342.","journal-title":"Transplantation"},{"issue":"7","key":"398_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/01.fpc.0000114745.08559.db","volume":"14","author":"E Schaeffeler","year":"2004","unstructured":"Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004;14(7):407\u201317.","journal-title":"Pharmacogenetics."},{"issue":"1","key":"398_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/apt.13835","volume":"45","author":"J Kirchgesner","year":"2017","unstructured":"Kirchgesner J, Lemaitre M, Rudnichi A, Racine A, Zureik M, Carbonnel F, et al. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009\u20132014. Aliment Pharmacol Ther. 2017;45(1):37\u201349.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"398_CR37","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1002\/ibd.21662","volume":"17","author":"X Roblin","year":"2011","unstructured":"Roblin X, Oussalah A, Chevaux JB, Sparrow M, Peyrin-Biroulet L. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm Bowel Dis. 2011;17(12):2480\u20137.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"398_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/rheumatology\/keh001","volume":"43","author":"KT Oh","year":"2004","unstructured":"Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxford). 2004;43(2):156\u201363.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"398_CR39","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1365-2036.2004.02124.x","volume":"20","author":"J Winter","year":"2004","unstructured":"Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(6):593\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"398_CR40","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1111\/j.1572-0241.2005.41900.x","volume":"100","author":"MC Dubinsky","year":"2005","unstructured":"Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn\u2019s disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005;100(10):2239\u201347.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"398_CR41","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2217\/14622416.7.5.783","volume":"7","author":"ME Akker-van Marle van den","year":"2006","unstructured":"van den Akker-van Marle ME, Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, Gutierrez de Mesa E, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics. 2006;7(5):783\u201392.","journal-title":"Pharmacogenomics."},{"issue":"2","key":"398_CR42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00408-009-9217-8","volume":"188","author":"JT Hagaman","year":"2010","unstructured":"Hagaman JT, Kinder BW, Eckman MH. Thiopurine S-methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung. 2010;188(2):125\u201332.","journal-title":"Lung"},{"issue":"1","key":"398_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jval.2013.10.007","volume":"17","author":"AJ Thompson","year":"2014","unstructured":"Thompson AJ, Newman WG, Elliott RA, Roberts SA, Tricker K, Payne K. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Value Health. 2014;17(1):22\u201333.","journal-title":"Value Health."},{"key":"398_CR44","doi-asserted-by":"publisher","first-page":"f1049","DOI":"10.1136\/bmj.f1049","volume":"346","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;346:f1049.","journal-title":"BMJ"},{"issue":"6","key":"398_CR45","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2217\/pgs.11.32","volume":"12","author":"WG Newman","year":"2011","unstructured":"Newman WG, Payne K, Tricker K, Roberts SA, Fargher E, Pushpakom S, et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics. 2011;12(6):815\u201326.","journal-title":"Pharmacogenomics."},{"issue":"2","key":"398_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1570-0232(02)00130-7","volume":"773","author":"D Anglicheau","year":"2002","unstructured":"Anglicheau D, Sanquer S, Loriot MA, Beaune P, Thervet E. Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic-phenotypic correlation. J Chromatogr B. 2002;773(2):119\u201327.","journal-title":"J Chromatogr B"},{"issue":"23","key":"398_CR47","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/jnci\/91.23.2001","volume":"91","author":"MV Relling","year":"1999","unstructured":"Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91(23):2001\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"398_CR48","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/rheumatology\/38.7.640","volume":"38","author":"MA Naughton","year":"1999","unstructured":"Naughton MA, Battaglia E, O\u2019Brien S, Walport MJ, Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford). 1999;38(7):640\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"398_CR49","doi-asserted-by":"publisher","first-page":"944","DOI":"10.2169\/internalmedicine.38.944","volume":"38","author":"S Ishioka","year":"1999","unstructured":"Ishioka S, Hiyama K, Sato H, Yamanishi Y, McLeod HL, Kumagai K, et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med. 1999;38(12):944\u20137.","journal-title":"Intern Med"},{"issue":"69","key":"398_CR50","first-page":"399","volume":"53","author":"JP Gisbert","year":"2006","unstructured":"Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology. 2006;53(69):399\u2013404.","journal-title":"Hepatogastroenterology."},{"key":"398_CR51","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"issue":"5","key":"398_CR52","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/tpj.2017.21","volume":"17","author":"M Verbelen","year":"2017","unstructured":"Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17(5):395\u2013402.","journal-title":"Pharmacogenomics J."},{"issue":"4","key":"398_CR53","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/bcp.12226","volume":"77","author":"L Lennard","year":"2014","unstructured":"Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2014;77(4):704\u201314.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-019-00398-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40291-019-00398-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-019-00398-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T18:08:56Z","timestamp":1721153336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40291-019-00398-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1007\/s40291-019-00398-x","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"8 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors (KV, IDZ, MAL, GC and NP) declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not involve human subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}